Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts that U.S. and European patent expiry of Pfizer's Norvasc will result in generics erosion that will constrain the hypertension drug market.

"In an attempt to protect its franchise, Pfizer has marketed Caduet, a combination of the blockbuster antihypertensive Norvasc and the blockbuster statin Lipitor," said Ruth Brown, Ph.D., analyst at Decision Resources. "This combination is currently the only therapy attempting to address global cardiovascular risk, and we believe it will attain blockbuster status."

The new Pharmacor study entitled Hypertension also finds that only one- third of drug-treated hypertensive patients achieve blood pressure goals.

"The reasons for low attainment of blood pressure goals are poor patient compliance with antihypertensive treatment regimens and suboptimal use of pharmacotherapy by primary care physicians," continued Dr. Brown.

About Hypertension

Hypertension is a common disorder in which blood pressure remains abnormally high. The aging demographic and the increasingly sedentary lifestyles will increase the number of prevalent cases of hypertension over the next ten years.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

   For more information, contact:     Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,

BioStratum and Otsuka to Enter the Diabetic Nephropathy Drug Market with New Advanced Glycation End Product Inhibitors

View Now